Bioventus (BVS) Total Current Liabilities (2020 - 2026)

Bioventus' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $148.1 million for Q1 2026.

• Quarterly Total Current Liabilities fell 15.25% year-over-year to $148.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.1 million (down 15.25% YoY) and the FY2025 annual result came in at $160.4 million, down 23.77% from the prior year.
• Total Current Liabilities was $148.1 million for Q1 2026 at Bioventus, down from $160.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $304.0 million in Q4 2022 and bottomed at $148.1 million in Q1 2026.
• A 5-year average of $196.0 million and a median of $179.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 79.44% — and 2023, when it slumped 44.22%.
• Bioventus' Total Current Liabilities stood at $304.0 million in 2022, then slumped by 42.27% to $175.5 million in 2023, then increased by 19.89% to $210.4 million in 2024, then retreated by 23.77% to $160.4 million in 2025, then dropped by 7.66% to $148.1 million in 2026.
• Business Quant data shows BVS's Total Current Liabilities at $148.1 million in Q1 2026, $160.4 million in Q4 2025, and $161.8 million in Q3 2025.